Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19

References

• World Health Organization. WHO director-general’s remarks at the media briefing on 2019-nCoV on 11 February 2020. Ed; 2020 [cited 2020 Apr 2]. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020
   Google Scholar
• Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020. doi:10.1056/NEJMoa2001316.
   Web of Science ®Google Scholar
• Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, Zimmer T, Thiel V, Janke C, Guggemos W, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970–71. doi:10.1056/NEJMc2001468.
   PubMed Web of Science ®Google Scholar
• Chen WH, Chag SM, Poongavanam MV, Biter AB, Ewere EA, Rezende W, Seid CA, Hudspeth EM, Pollet J, McAtee CP, et al. Optimization of the production process and characterization of the yeast-expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS vaccine candidate. J Pharm Sci. 2017;106(8):1961–70. doi:10.1016/j.xphs.2017.04.037.
   PubMed Web of Science ®Google Scholar
• Jiang S, Bottazzi ME, Du L, Lustigman S, Tseng CT, Curti E, Jones K, Zhan B, Hotez PJ. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines. 2012;11(12):1405–13. doi:10.1586/erv.12.126.
   PubMed Web of Science ®Google Scholar
• Chen WH, Du L, Chag SM, Ma C, Tricoche N, Tao X, Seid CA, Hudspeth EM, Lustigman S, Tseng CT, et al. Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Hum Vaccin Immunother. 2014;10(3):648–58. doi:10.4161/hv.27464.
   PubMed Web of Science ®Google Scholar
• Bian C, Zhang X, Cai X, Zhang L, Chen Z, Zha Y, Xu Y, Xu K, Lu W, Yan L, et al. Conserved amino acids W423 and N424 in receptor-binding domain of SARS-CoV are potential targets for therapeutic monoclonal antibody. Virology. 2009;383(1):39–46. doi:10.1016/j.virol.2008.09.029.
   PubMed Web of Science ®Google Scholar
• Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Hu Y, Song Z-G, Tao Z-W, Tian J-H, Pei -Y-Y, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–269.
   Google Scholar
• Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.
   Google Scholar
• Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020. Advance online publication.
   Web of Science ®Google Scholar
• Zeng LP, Ge XY, Peng C, Tai W, Jiang S, Du L, Shi ZL. Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses. Sci China Life Sci. 2017;60(12):1399–402. doi:10.1007/s11427-017-9189-3.
   PubMed Web of Science ®Google Scholar
• He Y, Li J, Heck S, Lustigman S, Jiang S. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. J Virol. 2006;80(12):5757–67. doi:10.1128/JVI.00083-06.
   PubMed Web of Science ®Google Scholar
• He Y, Lu H, Siddiqui P, Zhou Y, Jiang S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol. 2005;174(8):4908–15. doi:10.4049/jimmunol.174.8.4908.
   PubMed Web of Science ®Google Scholar
• Ter Meulen J, van den Brink EN, Poon LL, Marissen WE, Leung CS, Cox F, Cheung CY, Bakker AQ, Bogaards JA, van Deventer E, et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 2006;3(7):e237. doi:10.1371/journal.pmed.0030237.
   PubMed Web of Science ®Google Scholar
• Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, Lu L, Jiang S, Yang Z, Wu Y, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerging Microbes Infect. 2020;9(1):382–85. doi:10.1080/22221751.2020.1729069.
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;eabb2507. doi:10.1126/science.abb2507.
   Web of Science ®Google Scholar
• Ter Meulen J, Bakker AB, van den Brink EN, Weverling GJ, Martina BE, Haagmans BL, Kuiken T, de Kruif J, Preiser W, Spaan W, et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet. 2004;363(9427):2139–41. doi:10.1016/S0140-6736(04)16506-9.
   PubMed Web of Science ®Google Scholar
• van den Brink EN, Ter Meulen J, Cox F, Jongeneelen MA, Thijsse A, Throsby M, Marissen WE, Rood PM, Bakker AB, Gelderblom HR, et al. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J Virol. 2005;79(3):1635–44. doi:10.1128/JVI.79.3.1635-1644.2005.
   PubMed Web of Science ®Google Scholar
• Prabakaran P, Gan J, Feng Y, Zhu Z, Choudhry V, Xiao X, Ji X, Dimitrov DS. Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J Biol Chem. 2006;281(23):15829–36. doi:10.1074/jbc.M600697200.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Chakraborti S, He Y, Roberts A, Sheahan T, Xiao X, Hensley LE, Prabakaran P, Rockx B, Sidorov IA, et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A. 2007;104(29):12123–28. doi:10.1073/pnas.0701000104.
   PubMed Web of Science ®Google Scholar
• Hwang WC, Lin Y, Santelli E, Sui J, Jaroszewski L, Stec B, Farzan M, Marasco WA, Liddington RC. Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R. J Biol Chem. 2006;281(45):34610–16. doi:10.1074/jbc.M603275200.
   PubMed Web of Science ®Google Scholar
• Rockx B, Corti D, Donaldson E, Sheahan T, Stadler K, Lanzavecchia A, Baric R. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J Virol. 2008;82(7):3220–35. doi:10.1128/JVI.02377-07.
   PubMed Web of Science ®Google Scholar